• CORRECTION: This story was modified on Feb. 15, 2016 to reflect the Institute for Clinical & Economic Review’s final conclusion that the price of the Novartis drug Entresto should be 9% lower. The 17% figure originally cited in the article was the group’s preliminary finding.
Volume 94 Issue 7 | p. 6 | News of The Week
Issue Date: February 15, 2016 | Web Date: February 11, 2016

Novartis Tags Price Of Heart Drug To Patient Outcomes

Pharmaceuticals: Deal with two insurers is an early foray into performance-based pricing
Department: Business
News Channels: Biological SCENE
Keywords: patient outcomes, performance-based pricing, congestive heart failure, enzyme

Novartis has entered a performance-based pricing pact with U.S. health insurance majors Cigna and Aetna for Entresto, its new congestive heart failure drug. The novel deal is an early foray into crafting payment schemes based on patient outcomes and comes as drug companies are under pressure to lower prices.

Cigna says the deal ties the price of Entresto to how well it improves the health of patients relative to its performance in clinical trials. The . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society